This webcast is directed primarily to oncologists, registered nurses, physician assistants, nurse practitioners and pharmacists interested in new developments for treatment of non-small-cell lung cancer (NSCLC).
Statement of Need/Program Overview
This webcast is intended to improve care of patients with NSCLC by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of molecular profiling and personalized therapies at various stages of clinical development will be given significant focus. This enduring online activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.
Recommends version 6.x browsers or higher from Microsoft or Netscape. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of content. These activities will be marked as such and will provide links to the required software. Required software may include:
Windows Media Player
RealNetworks RealOne Player
VLC Media Player
A. Webb Roberts Center for CME of Baylor Health Care System observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support. To contact CME Provider, call 1-214-820-2317.
COURSE VIEWING REQUIREMENTS
Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this webcast. During the period October 24, 2013 through October 24, 2014 participants must read all of the material and study the educational webcast.
INSTRUCTIONS FOR COURSE PARTICIPATION
This webcast includes text, graphics, and may include multimedia features. There are no fees for participating in or receiving credit for this webcast.
Click on all of the "medical education webcast" links and review the content presented. You must view all of the content to proceed to the post-test.
Read, complete, and submit answers to the post-test questions and evaluation questions online. You must answer all missed questions until you get them correct.
Participants must receive a test score of 100% in order to proceed to the course evaluation, and they must respond to all evaluation questions to receive a letter of credit.
If needed, you may save your answers and return to complete your course at a later date. You can find your saved course by selecting "Your Course History" on the left navigation bar. Then select "View" next to the course you would like to complete.
LETTER OF CREDIT & TRANSCRIPTS
After submitting the webcast evaluation, you may access your letter of credit by selecting "Your Certificates" on the left navigation bar.
Select "Credit" to view letters of credit onscreen and print from your browser. You may print the letter of credit, but you may not alter the letter of credit.
Your credits will be tallied and may be viewed by selecting "View your transcripts" in the "Your Account" area.
Sponsor:This webcast is jointly sponsored by A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet. For more information visit: www.cancernetus.com
This activity is supported by educational grants from: Genentech BioOncology and Lilly USA, LLC
Accreditation:This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet. The A. Webb Roberts Center for CME of Baylor Health Care System is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:The A. Webb Roberts Center for CME of Baylor Health Care System designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty Listing:Corey J. Langer, MD,
Professor of Medicine,
Director of Thoracic Oncology,
Abramson Cancer Center,
University of Pennsylvania,
- Outline the clinical data supporting the optimal use of angiogenesis agents and MET inhibitors in the treatment of lung cancer
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:
Corey J. Langer, MD
Speaker's Bureau: Lilly USA, LLC, OSI Pharmaceuticals, Imclone-BMS
Advisory Board: BMS, Imclone, Sanofi-aventis, Pfizer, Lilly USA, LLC, Amgen, Astrazeneca, Novartis, Genentech, Bayer/Onyx, Celgene (Abraxis), Abbott Laboratories, Morphotek, Clarient, Caris DX, Boehringer-Ingelheim, Synta
Research Funding: BMS, Pfizer, Lilly USA, LLC, Genentech (Roche), OSI Pharmaceuticals (Astellas), Merck, GSK, Nektor, Daiichi-Sankyo
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:
Kamatham A. Naidu, PhD (CancerNet): No relevant financial relationships
All other individuals in a position to control content have no relevant financial relationships to disclose.